New drug discovery centre with screening capabilities opens in Australia
The National Drug Discovery Centre (NDDC) has opened in Australia, with support from the government to subsidise the screening of medicinal compounds.
List view / Grid view
The National Drug Discovery Centre (NDDC) has opened in Australia, with support from the government to subsidise the screening of medicinal compounds.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.
New research has revealed that despite a rising number of women in STEM publishing papers, there is a large gender difference due to females leaving academia.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
Boris Johnson, the Prime Minister of the UK, has announced a new Global Talent visa for researchers and scientists which will fast track those in certain fields.
The Cubis® II balance, with pharma package, contains all the technical controls to support compliance with common regulations.
The two organisations have entered into a two-year alliance to improve scientific exchange in the drug discovery industry.
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
President Trump has announced his intent to nominate Stephen Hahn as Commissioner of Food and Drugs at the Department of Health and Human Services.
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
The British Journal of Pharmacology has recommended that all studies it publishes should address sex as an experimental variable.
The ISCT is objecting linking the benefits of cellular immunotherapy with third party offerings of T-cell banking for future therapeutics.